Psychedelic Medicine
FAQ 2026

Oracle confidence: 78%.78% CONF Compass Pathways (CMPS) has hit primary endpoints in two Phase 3 trials — COMP005 (June 2025) and COMP006 (February 2026). The FDA issued a priority review voucher for psilocybin in April 2026. NDA submission is expected Q3 2026, with an approval window of Q4 2026 to Q1 2027. The primary risk is FDA requesting additional data on SSRI interaction protocols. Full tracker →

Multiple Phase 2 and Phase 3 trials are active. Compass Pathways' COMP360 (synthetic psilocybin, 25mg) has the most advanced regulatory position. USONA Institute is pursuing a separate NDA for naturally-sourced psilocybin for MDD. Johns Hopkins, NYU Langone, and UCSF all have active Phase 2 programs. Imperial College London has published landmark neuroimaging studies showing psilocybin's mechanism via Default Mode Network modulation. OOTWOracle scrapes ClinicalTrials.gov daily for new trial registrations and status updates.

FDA Breakthrough Therapy Designation has been granted for treatment-resistant depression (TRD) and major depressive disorder (MDD). Clinical evidence also supports efficacy for: end-of-life anxiety/existential distress (cancer patients), alcohol use disorder, nicotine/tobacco dependence, OCD, and anorexia nervosa (early trials). Psilocybin is not a broad antidepressant — it works best in structured therapeutic settings with preparation and integration support.

Psilocybin remains Schedule I federally. State-level legal frameworks: Oregon (Measure 109, 2020) — regulated therapeutic use with licensed facilitators, services launched 2023. Colorado (Prop 122, 2022) — natural medicine health centers opening 2024-2025. Washington DC (Initiative 81, 2020) — decriminalized but no regulated access. Several cities have decriminalized possession (Oakland, Santa Cruz, Ann Arbor, Detroit, Seattle, Portland).

A 2026 mechanistic paper examined fluoxetine-psilocybin interactions and demonstrated interference patterns that the FDA must address for active INDs enrolling SSRI patients. The FDA is more likely to issue formal washout-period guidance (requiring patients to taper off SSRIs before treatment) than to pause psilocybin development altogether. OOTWOracle tracks this as a complication, not a disqualification — and considers formal guidance before end of 2026 more probable than not.

In June 2026 a viral headline claimed "single dose of psilocybin may reverse Alzheimer's cognitive decline." OOTWOracle's swarm flagged it at 81% confidence and issued a counter-prediction: no peer-reviewed Phase II+ trial confirming this result publishes before 2027 [73% confidence]. The underlying preclinical research on neuroplasticity is real and promising, but Alzheimer's has defeated every drug candidate for 20 years — human clinical proof requires controlled trials with consent protocols, safety monitoring, and peer review. The hope is genuine; the headline is approximately 3 years early. Full analysis →

No. The FDA issued a Complete Response Letter (CRL) in August 2024 rejecting MAPS PBC's NDA for MDMA-assisted therapy for PTSD. The primary concerns: functional unblinding (participants know if they received MDMA vs. placebo), potential for abuse, and insufficient evidence of durability. MAPS resubmitted a Modified NDA in early 2026 with additional data. OOTWOracle tracks re-submission progress, FDA meeting schedules, and congressional advocacy signals daily. Full hub →

MAPS Phase 3 trials (MAPP1 and MAPP2) showed 67-71% of participants no longer met PTSD diagnostic criteria after three MDMA-assisted therapy sessions, compared to 32-48% for placebo. Effect sizes are among the largest ever recorded for a PTSD intervention. Australia approved MDMA therapy in February 2023, making it the first country to do so. The science is strong; the FDA's hesitation is primarily about the blinding methodology and long-term safety monitoring.

OOTWOracle's current assessment: 2027-2028 is the realistic window for FDA approval, assuming MAPS' modified NDA successfully addresses the CRL concerns. The PDUFA date for the re-submission will determine the review timeline. Congressional pressure via veterans' advocacy groups (particularly for combat PTSD) is a tailwind. A negative second review would set the timeline back to 2029+.

Ibogaine is a psychoactive alkaloid from the African iboga shrub. It has shown remarkable results for opioid use disorder (OUD) and addiction treatment — some studies report near-complete interruption of opioid withdrawal in a single session. It is particularly significant in the veterans' community as a potential treatment for treatment-resistant PTSD and traumatic brain injury (TBI). It remains illegal in the US due to cardiac risk: ibogaine prolongs the QT interval, which has caused deaths in unsupervised settings. Full hub →

Not before 2028-2030. The cardiac liability is the primary barrier. However, two parallel paths are active: (1) DemeRx and other sponsors developing oxa-noribogaine — a synthetic ibogaine analog with significantly reduced QT prolongation risk. OOTWOracle predicts a major ibogaine sponsor will pivot to oxa-noribogaine within 18 months. (2) Stanford's ibogaine + cardiac safety monitoring protocol, published in Nature Medicine, provides a potential framework for conditional FDA approval. The Trump executive order's $50M state research grants are specifically accelerating ibogaine safety research. Oracle confidence on formal FDA cardiac safety guidance: 82%.

Veterans' advocacy is the most powerful political force behind ibogaine legalization. Texas passed legislation funding $50M for ibogaine research, primarily for veteran PTSD and opioid addiction treatment. The Trump April 2026 executive order specifically includes ibogaine in the veterans' fast-track mandate. OOTWOracle gives Senate Veterans Affairs Committee holding ibogaine-specific hearings a 78% probability. OOTW Veterans access program →

Yes. Ketamine is the only currently FDA-approved psychedelic-adjacent therapy. Esketamine (Spravato) is FDA-approved for treatment-resistant depression (2019) and MDD with suicidal ideation (2020) — administered as a nasal spray in certified healthcare settings. Racemic ketamine infusions are legal as off-label use of an FDA-approved anesthetic — widely available at ketamine clinics across the US. Full hub →

OOTWOracle tracks several converging risk signals for the ketamine industry in 2026. DEA enforcement actions targeting ketamine clinics are running 3x above the 2025 baseline. Rapid clinic expansion, minimal regulatory oversight, and growing diversion patterns historically precede federal enforcement sweeps — OOTWOracle rates a significant DEA enforcement action in at least five states as more probable than not before year-end. The industry needs voluntary quality standards and self-regulation to avoid the kind of crackdown that would set back legitimate therapeutic access.

On April 18, 2026, President Trump signed an executive order directing fast-track FDA review of psychedelic medicines for veterans and first responders. Key provisions: mandatory FDA expedited review pathways for psychedelic therapies with veteran application; $50M in federal grants to state research programs; a conditional rescheduling pathway for ibogaine and psilocybin when FDA approves; expansion of the VA pilot psychedelic therapy program. OOTWOracle rates the impact probability at 88% — the highest-confidence prediction in the current archive. Full analysis →

DEA rescheduling moves a substance from Schedule I (no accepted medical use, high abuse potential) to a lower schedule allowing medical use. FDA approval triggers a mandatory DEA rescheduling review, but the process takes years — public comment periods, inter-agency coordination, rule-making. OOTWOracle's prediction: no psychedelic substance completes full federal rescheduling before 2028, regardless of FDA approvals, due to the structural inertia of the rescheduling process.

The BREAKTHROUGH Act (Breakthrough Therapies for Veterans Act) is congressional legislation that would require the VA to develop protocols for psychedelic-assisted therapy access for veterans. It has bipartisan support and is being tracked by OOTWOracle as one of the most likely pieces of psychedelic legislation to advance in 2026, bolstered by the Trump EO's momentum.

Regulated therapeutic access: Oregon (psilocybin, Measure 109), Colorado (psilocybin + DMT + ibogaine + mescaline, Prop 122). Decriminalization (possession): Washington DC, Oakland CA, Santa Cruz CA, Seattle WA, Denver CO, Ann Arbor MI, Somerville MA, Cambridge MA, Northampton MA, Detroit MI, Portland OR. Legislative momentum: California, New York, Arizona, and Texas all have active psychedelic therapy bills in 2026.

OOTWOracle tracks these primary publicly traded companies daily: Compass Pathways (CMPS) — psilocybin, most advanced FDA position; ATAI Life Sciences (ATAI) — portfolio company holding multiple psychedelic programs; MindMed (MMED) — LSD analog MM-120 for generalized anxiety disorder, Phase 3. June 2026 signal: MMED +2.9% while CMPS -2.1% — a divergence indicating markets are sorting between compounds with clear FDA runways (psilocybin) and those with regulatory uncertainty.

OOTWOracle provides intelligence, not investment advice. What the data shows: the sector is high-volatility, binary-outcome — FDA decisions move stocks 40-80% in a day. The Trump EO and Compass Phase 3 success have been tailwinds. Risks include: FDA CRL for MDMA creating sector-wide fear, DEA enforcement headwinds for ketamine operators, and the long timeline between approval and commercial revenue. Consult a licensed financial advisor for investment decisions.

OOTWOracle is a daily AI intelligence engine covering the psychedelic medicine ecosystem. Every morning it: (1) scrapes 460+ signals from PubMed, ClinicalTrials.gov, financial markets, Congressional records, Reddit, and news; (2) runs a multi-agent simulation (MiroFish OASIS) — 8 AI personas representing regulators, researchers, investors, advocates, journalists, and policymakers debating the day's signals; (3) generates 4-6 falsifiable, confidence-scored predictions with specific resolve dates; (4) publishes a daily oracle report with analysis of the current signal, deeper pattern, and the highest positive trajectory. It has published 43 reports and 223+ predictions since April 27, 2026.

All predictions are publicly archived and accuracy is tracked as predictions resolve. The system is designed for calibrated honesty over false confidence — a 73% confidence prediction should be right approximately 73% of the time. OOTWOracle avoids overclaiming. You can verify accuracy independently at predictions.json and the predictions tracker.

Yes. All content is published under CC BY 4.0 — free to use with attribution. Machine-readable endpoints: predictions.json (today's predictions), all_predictions.json (full archive), feed.json (daily reports), OpenAPI schema. AI agents: see llms.txt and developer documentation.

Classical psychedelics (psilocybin, LSD, DMT) primarily act as serotonin 2A receptor agonists. This disrupts the Default Mode Network (DMN) — the brain system responsible for self-referential thought and the "ego." Under psychedelics, rigid mental patterns become temporarily plastic, allowing therapeutic re-processing of trauma and depression. Neuroimaging research (Imperial College London, Johns Hopkins) shows increased cross-network connectivity during psychedelic states. This neuroplasticity effect is the scientific basis for psychedelic-assisted therapy.

Psilocybin (serotonin 2A agonist) — produces visual/perceptual changes and profound shifts in meaning-making. Best evidence for depression and end-of-life anxiety. Duration: 4-6 hours. MDMA (releases serotonin, dopamine, norepinephrine) — produces empathy, emotional openness, and reduced fear. Best evidence for PTSD. Duration: 3-5 hours. Ibogaine (complex multi-receptor activity including serotonin, dopamine, opioid systems) — produces extended visionary experiences and appears to "reset" addiction pathways. Best evidence for opioid addiction. Duration: 18-36 hours. Carries cardiac risk.

Key figures tracked by OOTWOracle: Matthew Johnson (Johns Hopkins — psilocybin for addiction), Robin Carhart-Harris (UCSF — psilocybin mechanism, neuroimaging), Charles Raison (University of Wisconsin — psilocybin for MDD), Rick Doblin (MAPS — MDMA), Nolan Williams (Stanford — ibogaine + cardiac safety), Alan Davis (Ohio State — mystical experiences and outcomes). Institutions: Johns Hopkins Center for Psychedelic and Consciousness Research, UCSF Psychedelics Division, NYU Langone Psychedelic Medicine, Imperial Centre for Psychedelic Research.

"Set" refers to mindset — the participant's intentions, psychological state, and preparation. "Setting" refers to the physical and social environment — a calm, safe space with trained therapists present. The clinical evidence strongly supports that therapeutic outcomes depend heavily on set and setting, not just the drug dose. This is why all FDA-track psychedelic therapies involve extensive preparation, supervised sessions, and integration therapy — it is the combination of drug and therapeutic container that produces the outcome.